NDAORALCAPSULE
Approved
Nov 1979
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
1/8 — Limited
Drug data last refreshed 13h ago · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
CENTRAX (prazepam) is an oral benzodiazepine capsule approved by Pfizer in 1979 for anxiety disorders. The drug works through central nervous system depression via GABAergic mechanisms, though specific indications and mechanism-of-action details are not fully documented in available records. It represents a legacy anxiolytic in a highly competitive therapeutic class.
LOE Approaching
As a legacy product approaching loss of exclusivity with moderate competitive pressure (30/100), commercial teams are likely focused on defensive strategies rather than expansion.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
Working on CENTRAX offers limited career growth opportunity given its LOE-approaching status and zero linked job openings. Professionals on this team should expect defensive commercial work and should plan career mobility toward growth-stage products.
Brand ManagerField Sales Representative
Worked on CENTRAX at Pfizer? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.